These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31015016)

  • 1. Microsatellite Instability May Predict Response to Sipuleucel-T in Patients With Prostate Cancer.
    Zhang KJ; Schneider BP; Albany C
    Clin Genitourin Cancer; 2019 Jun; 17(3):238-239. PubMed ID: 31015016
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.
    McNamara M; Berry W
    Clin Genitourin Cancer; 2015 Oct; 13(5):e361-4. PubMed ID: 25735199
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
    Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
    Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
    Crawford ED; Petrylak DP; Higano CS; Kibel AS; Kantoff PW; Small EJ; Shore ND; Ferrari A
    Can J Urol; 2015 Dec; 22(6):8048-55. PubMed ID: 26688132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
    Dorff TB; Wilkins C; Hepgur M; Quinn DI
    Clin Genitourin Cancer; 2014 Apr; 12(2):e55-8. PubMed ID: 24331572
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.
    Bilen MA; Hess KR; Subudhi SK; Aparicio A; Kim J; Zurita-Saavedra AJ; Araujo JC; Corn PG; Stover J; Lin SH; Logothetis CJ; Tu SM
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):583-589. PubMed ID: 28730293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.
    Antonarakis ES; Small EJ; Petrylak DP; Quinn DI; Kibel AS; Chang NN; Dearstyne E; Harmon M; Campogan D; Haynes H; Vu T; Sheikh NA; Drake CG
    Clin Cancer Res; 2018 Oct; 24(19):4662-4671. PubMed ID: 29858218
    [No Abstract]   [Full Text] [Related]  

  • 9. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
    Small EJ; Lance RS; Gardner TA; Karsh LI; Fong L; McCoy C; DeVries T; Sheikh NA; GuhaThakurta D; Chang N; Redfern CH; Shore ND
    Clin Cancer Res; 2015 Sep; 21(17):3862-9. PubMed ID: 25925891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
    GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
    Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
    George DJ; Nabhan C; DeVries T; Whitmore JB; Gomella LG
    Cancer Immunol Res; 2015 Sep; 3(9):1063-9. PubMed ID: 25943532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
    Mulders PF; De Santis M; Powles T; Fizazi K
    Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.
    Zhang L; Kandadi H; Yang H; Cham J; He T; Oh DY; Sheikh NA; Fong L
    Cancer Immunol Res; 2020 Dec; 8(12):1496-1507. PubMed ID: 32967912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
    Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
    Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
    Gong CL; Hay JW
    J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer.
    Gaines KK
    Urol Nurs; 2012; 32(2):95-8. PubMed ID: 22690466
    [No Abstract]   [Full Text] [Related]  

  • 20. [Unapproved drugs--radium-223, Sipuleucel-T, ketoconazole].
    Nishiyama T
    Nihon Rinsho; 2016 May; 74 Suppl 3():649-52. PubMed ID: 27344810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.